Page last updated: 2024-11-10

wedelolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
WedeliagenusA plant genus of the family ASTERACEAE. Members contain wedelolactone and wedeloside.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
EcliptagenusA plant genus of the family ASTERACEAE. Members contain wedelolactone.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Eclipta prostrataspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Eclipta prostrataspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID5281813
CHEMBL ID97453
CHEBI ID10037
SCHEMBL ID601220
MeSH IDM0145637

Synonyms (55)

Synonym
CHEMBL97453 ,
chebi:10037 ,
LS-14463
W0015
wedelolactone, >=98% (hplc), powder
wedelolactone; 7-methoxy-5,11,12-trihydroxy-coumestan
K00058
SMP2_000112
wedelolactone
524-12-9
NCGC00163667-02
7-methoxy-5,11,12-trihydroxy-coumestan
NCGC00163667-01
1,8,9-trihydroxy-3-methoxy-6h-[1]benzofuro[3,2-c]chromen-6-one
1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one
bdbm50096619
1,8,9-trihydroxy-3-methoxy-benzo[4,5]furo[3,2-c]chromen-6-one
LMPK12090046
5,11,12-trihydroxy-7-methoxycoumestan
1,8,9-trihydroxy-3-methoxycoumestan
NCGC00163667-03
1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one
BRD-K53635676-001-01-5
unii-0k6l725gns
6h-benzofuro(3,2-c)(1)benzopyran-6-one, 1,8,9-trihydroxy-3-methoxy-
0k6l725gns ,
S9042
HMS2043P19
1,8,9-trihydroxy-3-methoxy-6h-benzofuro[3,2-c][1]benzopyran-6-one
7-methoxy-5,11,12-trihydroxycoumestan
AKOS015897173
1,8,9-trihydroxy-3-methoxy-6h-(1)benzofuro(3,2-c)chromen-6-one
BRD-K53635676-001-02-3
1,8,9-trihydroxy-3-methoxy-[1]benzoxolo[3,2-c]chromen-6-one
gtpl5551
SCHEMBL601220
CCG-208289
AC-34562
HB4124
FT-0698529
mfcd07778564
DTXSID60200408
wedelolactone, analytical standard
sr-05000002318
SR-05000002318-2
wedelolactone, european pharmacopoeia (ep) reference standard
BCP19859
1,8,9-trihydroxy-3-methoxy-6h-benzofuro[3,2-c]chromen-6-one
ikk inhibitor ii
Q6586709
A14804
CS-0009079
HY-N0551
A936784
B0005-464576

Research Excerpts

Overview

Wetelolactone (WDL) is a naturally isolated compound from Eclipta prostrata L. It is a multi-target natural plant coumestan exhibiting cytotoxicity towards cancer cells. WedelolActone is a multitarget natural plant compound with many pharmacological activities.

ExcerptReferenceRelevance
"Wedelolactone (WDL) is a naturally isolated compound from Eclipta prostrata L."( Phytochemical wedelolactone reverses obesity by prompting adipose browning through SIRT1/AMPK/ PPARα pathway via targeting nicotinamide N-methyltransferase.
Chen, C; Fang, M; Hong, X; Huang, J; Huang, R; Huang, X; Jin, X; Mi, Y; Peng, L; Qiu, Y; Ren, J; Wu, X; Yang, L; Yang, X; Yao, E; Zhao, Y; Zhou, Y; Zhuo, R, 2022
)
1.8
"Wedelolactone (WDL) is a coumestan compound derived from the Wedelia chinensis plant and has been demonstrated to exhibit anti-inflammatory properties."( The potential role of herbal extract Wedelolactone for treating particle-induced osteolysis: an in vivo study.
Chang, TK; Fang, HW; Huang, CH; Lin, TC; Lu, YC; Yeh, ST, 2022
)
1.72
"Wedelolactone (WDL) is a coumestan present in the plants Eclipta prostrata and Wedelia calendulacea which are used for treatment of a multitude of health problems in traditional medicine. "( Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle.
Marschall, M; Reuter, N; Ruhland, A; Stamminger, T; Svrlanska, A, 2020
)
3.44
"Wedelolactone is a multi-target natural plant coumestan exhibiting cytotoxicity towards cancer cells. "( Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.
Beneš, P; Damborský, J; Daniel, L; Kanický, V; Nehybová, T; Preisler, J; Šmarda, J; Spasojevič, I; Stiborek, M, 2017
)
3.34
"Wedelolactone (WDL) is a natural compound derived from Chinese herbal medicine Eclipta prostrate L, and has been reported to exhibit various effects potentially beneficial for human health. "( Wedelolactone, a plant coumarin, prevents vascular smooth muscle cell proliferation and injury-induced neointimal hyperplasia through Akt and AMPK signaling.
Huang, X; Jin, X; Jing, Z; Peng, L; Ren, J; Yang, L; Zhao, Y; Zhou, Y, 2017
)
3.34
"Wedelolactone is a multitarget natural plant compound with many pharmacological activities, including anti-inflammatory, anticancer, and antiosteoporosis. "( Wedelolactone Enhances Odontoblast Differentiation by Promoting Wnt/β-Catenin Signaling Pathway and Suppressing NF-κB Signaling Pathway.
Feng, X; Gu, Z; Huang, D; Lian, M; Lu, Q; Lu, X; Song, Y; Wang, C, 2018
)
3.37
"Wedelolactone is a major coumarin of Eclipta prostrata, which is used for preventing liver damage. "( Wedelolactone exhibits anti-fibrotic effects on human hepatic stellate cell line LX-2.
Cao, Y; Chen, J; Chen, X; Li, R; Pan, Y; Xia, Y; Xu, C, 2013
)
3.28
"Wedelolactone is an herbal medicine that is used to treat septic shock, hepatitis and venom poisoning. "( Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchymal stem cells.
Jang, HJ; Kim, EK; Kim, JK; Kim, JM; Kim, YH; Lee-Kwon, W; Lim, S; Park, EH; Ryu, SH; Suh, PG; Yea, K, 2012
)
3.26

Treatment

Wedelolactone decreased pro-inflammatory cytokine interleukin 1 beta (IL-1β) maturation by inhibiting caspase-1 activity. Pre-treated mice had clear alveolar cavity and lower neutrophil infiltration and interstitial thickness than HALI group.

ExcerptReferenceRelevance
"Wedelolactone pretreated mice had clear alveolar cavity and lower neutrophil infiltration and interstitial thickness than HALI group."( [Wedelolactone alleviates hyperoxia-induced acute lung injury by regulating ferroptosis].
Chen, M; Feng, B; Liu, J; Mei, H; Qin, S, 2023
)
2.54
"Pre-treatment with wedelolactone decreased pro-inflammatory cytokine interleukin 1 beta (IL-1β) maturation by inhibiting caspase-1 activity."( Wedelolactone suppresses IL-1β maturation and neutrophil infiltration in Aspergillus fumigatus keratitis.
Che, C; Cheng, M; Li, C; Lin, J; Lv, L; Yang, H; Zhao, W, 2019
)
2.28
"Treatment with wedelolactone, an IkappaB kinase inhibitor, or overexpression of an IkappaB super-repressor reduced cell viability, further implicating NFkappaB in pituitary tumor cell growth."( Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells.
Dhandapani, KM; Laird, MD; Vender, JR, 2008
)
0.69

Toxicity

ExcerptReferenceRelevance
" The QUIN is involved in the development of several toxic cascades which leads to the neuronal degeneration processes."( Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis.
Goli, D; S, M; T, P, 2018
)
0.88

Pharmacokinetics

ExcerptReferenceRelevance
" The present study aims to develop a sensitive, rapid and reliable liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the simultaneous estimation of mice plasma concentrations of LTL, WDL and APG using quercetin as an internal standard for the pharmacokinetic analysis."( LC-MS/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hansen solubility parameters for liquid-liquid extraction: Application to pharmacokinetics of Eclipta alba chloroform fraction.
Arya, KR; Arya, RK; Cheruvu, HS; Datta, D; Gayen, JR; Hussain, Z; Sharma, C; Singh, RK; Valicherla, GR; Yadav, NK, 2018
)
0.72

Bioavailability

ExcerptReferenceRelevance
"A decline in the bioavailability of nitric oxide (NO) that causes endothelial dysfunction is a hallmark of diabetes."( High glucose-induced IKK-Hsp-90 interaction contributes to endothelial dysfunction.
Centonze, VE; Konopinski, R; Mohan, S; Natarajan, M; Yan, B, 2009
)
0.35
" The objective of the present study is to enhance bioavailability of wedelolactone by its complexation with phosphatidyl choline and then formulating it as phyto-vesicles for hepatoprotective activity."( Development and characterization of phyto-vesicles of wedelolactone for hepatoprotective activity.
Dixit, VK; Gupta, NK; Upadhyay, K, 2012
)
0.86
"The extensive glucuronidation and methylation is responsible for the low oral bioavailability of WEL in rats."( Wedelolactone metabolism in rats through regioselective glucuronidation catalyzed by uridine diphosphate-glucuronosyltransferases 1As (UGT1As).
Chen, XY; Huang, XJ; Li, L; Peng, JL; Zhang, CF; Zheng, MY; Zhong, DF, 2016
)
1.88

Dosage Studied

ExcerptRelevanceReference
" A formula that combined the phytocompounds in the same proportions as in the herbal extract decreased the dosage of each compound required to achieve maximal AR inhibition."( Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells.
Chen, HY; Chen, LR; Hsiao, PW; Ke, FC; Lin, EH; Lin, FM; Tsai, MJ, 2007
)
0.34
" Hence, linear dose-response curves between RLuc activity and specific inhibitors were obtained, as was faster drug screening through real-time measurement of chemiluminescence."( An in vitro coupled transcription/translation reporter system for hepatitis C virus RNA-dependent RNA polymerase.
Chen, KJ; Hsu, SH; Lee, JC; Lin, CK; Tseng, CK, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
coumestansMembers of the class of benzofurochromene with a 6H-[1]benzofuro[3,2-c]chromene skeleton and its substituted derivatives. They are the 3,4-didehydroderivatives of pterocarpans.
delta-lactoneA lactone having a six-membered lactone ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.41500.003245.467312,589.2998AID2517; AID2572
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.85390.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency6.27100.125919.1169125.8920AID2549; AID2708; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency31.35405.623417.292931.6228AID485281
endonuclease IVEscherichia coliPotency5.62340.707912.432431.6228AID2565
phosphopantetheinyl transferaseBacillus subtilisPotency8.53980.141337.9142100.0000AID1490
shiga toxin 1 variant A subunitEscherichia coli O157:H7Potency25.72205.035416.193232.6037AID2320; AID493122; AID493123
shiga toxin 1 B subunitEscherichia coli O157:H7Potency7.98055.035413.848822.4921AID2320
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency26.05700.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency15.18610.540617.639296.1227AID2528
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency23.42210.02007.985839.8107AID504370; AID504374; AID504375
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency41.80360.010039.53711,122.0200AID1469; AID1479
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency23.42210.02007.985839.8107AID504370; AID504374; AID504375
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.21910.00798.23321,122.0200AID2546; AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency1.21770.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency4.46680.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency4.46680.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency4.46680.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency4.46680.01418.602439.8107AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)IC50 (µMol)10.00000.00090.97819.8200AID325761
Inhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)IC50 (µMol)10.00000.03901.40367.4000AID325762
Telomere resolvase ResTBorreliella burgdorferi B31IC50 (µMol)8.67008.67008.67008.6700AID565409
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)2.50000.00011.68479.3200AID7198
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)IC50 (µMol)5.18005.18007.32009.4000AID1757376
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Ki4.86551.19105.12919.9410AID1757374; AID1757378; AID1757386; AID1757387
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Carbonyl reductase [NADPH] 1Homo sapiens (human)IC50 (µMol)3.78000.40002.03003.7800AID347259
Carbonyl reductase [NADPH] 1Homo sapiens (human)Ki0.60000.06001.12503.4300AID347259
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.505710.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.497310.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.498810.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.504610.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.506510.0000AID7198
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.505710.0000AID7198
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)2.50000.00010.507510.0000AID7198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polycomb protein EEDHomo sapiens (human)Kd2.81332.80002.81332.8200AID1729436; AID1854199; AID1872389
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Kd3.64003.64003.64003.6400AID1757375
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (113)

Processvia Protein(s)Taxonomy
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
skeletal muscle contractionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
I-kappaB phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
Rho protein signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to xenobiotic stimulusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to toxic substanceInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
anatomical structure morphogenesisInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to acetateInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to lipopolysaccharideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of interferon-alpha productionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to hydroperoxideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
toll-like receptor 4 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to reactive oxygen speciesInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
non-canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to amino acidInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
striated muscle cell differentiationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to cholecystokininInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to cadmium ionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
spinal cord developmentPolycomb protein EEDHomo sapiens (human)
negative regulation of DNA-templated transcriptionPolycomb protein EEDHomo sapiens (human)
heterochromatin formationPolycomb protein EEDHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolycomb protein EEDHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
xenobiotic metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
glucocorticoid metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
cyclooxygenase pathwayCarbonyl reductase [NADPH] 1Homo sapiens (human)
epithelial cell differentiationCarbonyl reductase [NADPH] 1Homo sapiens (human)
vitamin K metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCarbonyl reductase [NADPH] 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein-containing complex bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
transcription corepressor bindingPolycomb protein EEDHomo sapiens (human)
protein bindingPolycomb protein EEDHomo sapiens (human)
enzyme activator activityPolycomb protein EEDHomo sapiens (human)
histone methyltransferase activityPolycomb protein EEDHomo sapiens (human)
identical protein bindingPolycomb protein EEDHomo sapiens (human)
nucleosome bindingPolycomb protein EEDHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
carbonyl reductase (NADPH) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorCarbonyl reductase [NADPH] 1Homo sapiens (human)
oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptorCarbonyl reductase [NADPH] 1Homo sapiens (human)
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NADP+) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
prostaglandin-E2 9-reductase activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
S-nitrosoglutathione reductase (NADPH) activityCarbonyl reductase [NADPH] 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
nucleusPolycomb protein EEDHomo sapiens (human)
nucleoplasmPolycomb protein EEDHomo sapiens (human)
chromosomePolycomb protein EEDHomo sapiens (human)
cytosolPolycomb protein EEDHomo sapiens (human)
ESC/E(Z) complexPolycomb protein EEDHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolCarbonyl reductase [NADPH] 1Homo sapiens (human)
extracellular exosomeCarbonyl reductase [NADPH] 1Homo sapiens (human)
extracellular vesicleCarbonyl reductase [NADPH] 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (121)

Assay IDTitleYearJournalArticle
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347253Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADP+2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684076Antimetastatic activity against human MDA-MB-231 cells assessed as inhibition of anchorage-independent colony formation after 21 days by inverted microscopy2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1757388Inhibition of G6PD in human OVCAR-3 cells assessed as thermal instability of the enzyme by CETSA analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID565412Inhibition of Borrelia burgdorferi telomere resolvase assessed as inhibition of telomere resolution at 10 uM2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete.
AID180506Inhibition of [3H]flunitrazepam binding to rat brain synaptosomes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation.
AID684077Antimetastatic activity against human MDA-MB-231 cells assessed as inhibition of wound closure activity up to 20 uM at 12 hrs by scratch motility assay2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID347257Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADPH2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1335041Potency index, ratio of coumestrol IC50 to compound IC50 for 5-lipoxygenase in pig leukocytes2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
A one-pot laccase-catalysed synthesis of coumestan derivatives and their anticancer activity.
AID1729436Binding affinity to EED (unknown origin) by surface plasmon resonance assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
AID684286Antiinvasive activity against human SKHEP1 cells2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684083Downregulation of MMP2 expression in human MDA-MB-231 cells at 5 to 20 uM after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347259Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation using isatin as substrate2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757375Binding affinity to G6PD (unknown origin) assessed as equilibrium dissociation constant by surface plasmon resonance assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347258Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as NADPH oxidation at 200 uM relative to isatin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID684078Antiinvasive activity against human MDA-MB-231 cells assessed as F-actin reorganization at 20 uM incubated 24 hrs post-serum starvation measured after 12 hrs by TRITC-conjugated phalloidin staining method2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684087Upregulation of TIMP1 expression in human MDA-MB-231 cells at 0.5 to 1 uM after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID565409Inhibition of Borrelia burgdorferi telomere resolvase by gel-based telomere resolution assay2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete.
AID347256Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADP+2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID565411Inhibition of Borrelia burgdorferi telomere resolvase assessed as reduction in DNA cleavage at 10 uM2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete.
AID1757389Inhibition of colony formation in human OVCAR-3 cells overexpressing G6PD incubated for 14 days by crystal violet staining based assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1757382Competitive inhibition of G6PD (unknown origin) assessed as Vmax at 2.2 to 11.1 uM using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347254Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in presence of NADPH2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID684075Cytotoxicity against human MDA-MB-231 cells at 25 to 100 uM after 24 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757378Competitive inhibition of G6PD (unknown origin) using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325761Inhibition of IKK-beta2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757374Non-competitive inhibition of G6PD (unknown origin) using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1872389Binding affinity to EED (unknown origin) assessed as dissociation constant SPR assay2022European journal of medicinal chemistry, Mar-05, Volume: 231Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347255Binding affinity to human recombinant carbonyl reductase 3 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in absence of cofactor2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1757381Competitive inhibition of G6PD (unknown origin) assessed as Vmax at 2.2 to 11.1 uM using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID347252Binding affinity to human recombinant carbonyl reductase 1 expressed in Escherichia coli assessed as thermal shift by differential scanning fluorimetry in absence of cofactor2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1854199Binding affinity to CM5 sensor chip immobilised EED (unknown origin) assessed as dissociation constant incubated for 270 secs by SPR analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Targeting EZH2 for cancer therapy: From current progress to novel strategies.
AID1757390Reversible inhibition of G6PD (unknown origin) using glucose-6-phosphate and NADP+ as substrate measured after dilution of 12XIC50 to 0.6XIC50 by dilution based analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID180507Tested for the inhibitory activity against rat kidney Na+, K+-ATPase2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325762Inhibition of IKK12007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757387Non-competitive inhibition of G6PD (unknown origin) using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757384Competitive inhibition of G6PD (unknown origin) assessed as Km at 2.2 to 11.1 uM using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684276Inhibition of IkappaBalpha phosphorylation in human MDA-MB-231 cells at 5 to 20 uM after 12 to 24 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684085Downregulation of MMP9 expression in human MDA-MB-231 cells at 0.5 to 1 uM after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684278Inhibition of ERK 1/2 phosphorylation in human MDA-MB-231 cells at 5 to 20 uM after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID693393Inhibition of wild type recombinant C terminal His6-tagged HCV1b NS5B Cdelta21 RNA dependent RNA polymerase activity expressed in Escherichia coli JM109 (DE3) using poly rA/U12 template primer by liquid scintillation counting2012European journal of medicinal chemistry, Dec, Volume: 58Discovery of new scaffolds for rational design of HCV NS5B polymerase inhibitors.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID684080Antiinvasive activity against human MDA-MB-231 cells pretreated for 12 hrs followed by compound-wash out measured after 12 hrs by Boyden chamber assay2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757385Non-competitive inhibition of G6PD (unknown origin) assessed as Km at 2.2 to 11.1 uM using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1335040Inhibition of 5-lipoxygenase in pig leukocytes using arachidonic acid as substrate2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
A one-pot laccase-catalysed synthesis of coumestan derivatives and their anticancer activity.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757380Non-competitive inhibition of G6PD (unknown origin) assessed as Vmax at 2.2 to 11.1 uM using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID684079Inhibition of FAK phosphorylation in human MDA-MB-231 cells after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757379Competitive inhibition of G6PD (unknown origin) assessed as Km at 2.2 to 11.1 uM using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID410102Inhibition of HCV 1b NS5B Cdelta21 polymerase2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
AID684088Upregulation of TIMP2 expression in human MDA-MB-231 cells at 1 to 3.5 uM after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757386Competitive inhibition of G6PD (unknown origin) using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1757376Inhibition of G6PD (unknown origin) assessed as reduction in 6-phospho-D-glucono-1,5-lactone and NADPH production using glucose-6-phosphate and NADP+ as substrate incubated for 15 mins by UV absorption photometry assay2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID7198Tested for the inhibitory activity against 5-lipoxygenase2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation.
AID684277Inhibition of IkappaBalpha phosphorylation in human MDA-MB-231 cells after 12 hrs by Western blot analysis2012European journal of medicinal chemistry, Oct, Volume: 56Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.
AID1757383Non-competitive inhibition of G6PD (unknown origin) assessed as Vmax at 2.2 to 11.1 uM using varying concentrations of G6P and NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID644333Inhibition of HCV genotype 1b recombinant N-His-tagged NS5B Cdelta21 polymerase expressed in Escherichia coli DH5alpha using [alpha-32P]UTP after 60 mins by liquid scintillation counting2012European journal of medicinal chemistry, Mar, Volume: 49Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1757377Non-competitive inhibition of G6PD (unknown origin) assessed as Km at 2.2 to 11.1 uM using glucose-6-phosphate and varying concentrations of NADP+ as substrate by Michaelis-Menten analysis2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Discovery and characterization of a novel glucose-6-phosphate dehydrogenase (G6PD) inhibitor via high-throughput screening.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1345243Human CBR1 (Prostaglandin synthases)2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1799899NS5B Inhibition Assay from Article 10.1111/cbdd.12105: \\Evaluation of Coumarin and Neoflavone Derivatives as HCV NS5B Polymerase Inhibitors.\\2013Chemical biology & drug design, May, Volume: 81, Issue:5
Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (123)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (2.44)18.7374
1990's2 (1.63)18.2507
2000's22 (17.89)29.6817
2010's69 (56.10)24.3611
2020's27 (21.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.52 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index5.72 (4.65)
Search Engine Demand Index48.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other120 (97.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]